Oral Health Regulatory & Market Alerts

The American Dental Association and British Dental Association have both formally stated that charcoal toothpastes lack clinical evidence for efficacy and carry documented enamel abrasivity risk. No charcoal toothpaste has achieved the ADA Seal of Acceptance, and the ADA has indicated the evidence basis for the seal cannot be met by charcoal formulations. Consumer interest has peaked and is declining. There is no clinically defensible pathway for maintaining charcoal as a primary oral care ingredient. Brands must either exit this format or replace the charcoal with an evidence-backed active (nHAp, PAP, CPC) with a new brand story.

EU Cosmetics Regulation restricts hydrogen peroxide concentration in consumer whitening products to 0.1% maximum. Products with higher concentrations require professional supervision and dispensing. US OTC allows up to 10% carbamide peroxide (equivalent ~3.5% HP). Brands operating across both markets face a compliance decision: operate market-specific SKU formulations, or reformulate globally to the EU-compliant standard (using PAP or blue covarine to substitute whitening efficacy). The EU-compliant approach avoids dual manufacturing complexity but requires investment in alternative whitening agent RCT evidence.

Nano-hydroxyapatite is approved for drug-equivalent remineralisation claims in Japan and the EU (as a cosmetic active). The FDA has not established OTC monograph status for nHAp in the US, meaning US brands cannot make drug-equivalent caries prevention claims. US brands using nHAp must frame claims cosmetically (strengthening, polishing, refreshing enamel) rather than as drug claims (preventing cavities). Monitor FDA pre-submission guidance and watch for industry-sponsored OTC monograph petitions. CRN and ADA may submit supportive dossiers in 2026 Sources

EPA is reassessing the maximum contaminant level (MCL) for fluoride in drinking water in 2026. This review is entirely separate from fluoride concentrations in toothpaste, which are regulated by the FDA OTC monograph and remain unchanged. Consumer confusion between water fluoride concerns and toothpaste fluoride safety is high. Brands should prepare clear, factual communications distinguishing the two regulatory domains. Anti-fluoride consumer sentiment may increase during the EPA review — proactive brand communication is advisable. Brands positioned in the nHAp or fluoride-free segment should be aware that conflation creates inadvertent benefit.

Peri-implantitis affects an estimated 20% of implant patients and is the leading cause of implant failure. Current recommendations (implant-safe interdental brushes, water irrigation, non-abrasive rinse) do not have a dedicated branded OTC product architecture. Dental hygienists are the recommendation channel for implant care products. The combination of growing implant prevalence, clinical urgency, and professional recommendation pathway creates a structural product opportunity Sources

S. salivarius K12 and M18 are demonstrating meaningful clinical outcomes in RCTs: reduction in halitosis, suppression of Streptococcus mutans, and periodontal pathogen inhibition. The oral probiotic category has no mainstream brand leader in the US. BLIS Technologies (NZ) holds the IP for the primary clinically validated strains. Lozenge/tablet delivery is mandatory for live organism survival. The dental hygienist recommendation channel is the most credible route to consumer adoption. A brand that secures licensed strain access, builds a clinical substantiation dossier, and establishes professional endorsement partnerships will define this category for 10+ years.

2025 RCT data confirms PAP non-inferiority to low-concentration carbamide peroxide for whitening shade improvement. EU compliance, enamel safety, and the absence of hydrogen peroxide sensitivity make PAP the whitening ingredient for premium-positioned pan-European brands. DTC brands (HiSmile, Spotlight) have established the category; mass-market brands have not yet followed. The premium retail opportunity — pharmacy premium whitening section, professionalcare adjacency — remains underexploited by major oral care manufacturers.

5–8% of GLP-1 medication users report dry mouth as a side effect. With 3M+ active US GLP-1 prescriptions and growing, the absolute patient cohort is significant and highly motivated. Biotene dominates the general dry mouth category but has no GLP-1-specific product or targeting. A GLP-1-positioned dry mouth spray or rinse — using existing proven actives (salivary enzyme complex, betaine, xylitol) — requires no new formulation development, only positioning and pharmacy placement strategy adjacent to GLP-1 prescription filling areas.